LEGN · Legend Biotech Corp

CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 50% versus second quarter of 2025 to approximately $657 million Expanded CARVYKTI ® availability to 348 global sites and 19 global markets with the launch of Ireland Achieved first clinical proof-of-concept for LB2501, an

BRIDGEWATER N.J., July 28, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) ( Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 a.m. ET on Tuesday, August 11, 2026, to review second quarter 2026 financial results.

Ying Huang, Ph.D., steps down as Chief Executive Officer and member of the Board of Directors; will remain as an advisor through August to support a smooth transition Alan Bash, current President of the CARVYKTI Business Unit, appointed Interim Chief Executive Officer Board has initiated a

BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced the pricing of an underwritten public offering of 7,700,000 American Depositary Shares (“ADSs”), each representing two

BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced that it has commenced an underwritten public offering of $225 million of American Depositary Shares (“ADSs”), each

Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 study Single infusion of LB2501 generated dose-dependent in vivo CAR-T expansion without lymphodepletion No dose-limiting toxicities, serious adverse

Promising Phase 1 data for LB2501, a potential first ‑ in ‑ class CD19/CD20 dual ‑ targeting in vivo CAR-T therapy, as an off-the-shelf, single-infusion treatment for B ‑ cell malignancies An ORR of 100% (6/6) was observed in the dose level 2 cohort, including CR rate of 83.3% (5/6) in patients

LB2102 demonstrated a manageable safety profile and encouraging clinical activity in solid tumors among heavily pretreated patients Responses observed at higher dose levels of LB2102 with an ORR of 28.6% and a DCR of 78.6%, with durable responses seen in some patients New CARVYKTI ® data continue

Preliminary results from Phase 1 data for LB2102 to reinforce early evidence of activity in solid tumors in a rapid oral presentation New data from the CARTITUDE-4 study to highlight a cytogenetic subgroup analysis of patients who responded to bridging therapy will be featured in a poster

CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 62% versus first quarter of 2025 to approximately $597 million CARVYKTI ® now available across 18 global markets, following recent launches in Italy, Poland, the Czech Republic, and Australia Advanced early-stage cell

Leading experts across cell therapy, oncology, and immunology will provide strategic input as Legend advances and expands beyond its current portfolio SOMERSET, N.J., May 04, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) ( Legend Biotech), a global leader in cell therapy, today

SOMERSET, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) ( Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, May 12, 2026, to review first quarter 2026 financial results.

CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $555 million and $1.9 billion for the fourth quarter and full year 2025, respectively Surpassed milestone of more than 10,000 patients treated with CARVYKTI ® CARVYKTI now available across 294 sites worldwide;